Investing in Growth Through Innovation
Interview with Marc Doyle, CEO of Arxada, which was created following the carve-out and sale of Lonza Specialty Ingredients to private equity firms Bain Capital and Cinven.
Topics
Ensuring API Supply Capacities for Europe and Beyond
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
Expert Statement: Jean-Baptiste Guillermin, Axplora
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Stephen D Drake, Kaneka Americas Holdings
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Christophe Girard, Siegfried
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Baburaj Krishnan, Aurigene Pharmaceutical Services
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Mark Muldowney, Sterling Pharma Solutions
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Srividya Ramakrishnan, Dr. Reddy’s Laboratories
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Ulrich Mayerhoeffer, Arxada
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Shawn Walker, Veranova
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Expert Statement: Kai Rossen, Euroapi
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Circular economy in Europe: building new synergies
The Serbian Elixir Group has made a name for itself as one of the leading producers of mineral fertilizers and phosphoric acid in Eastern Europe.
The Japanese Pharma Market
Japan continues to be one of the largest pharmaceutical markets in the world, making up approximately 7% of the global share. Historically, Japan has been viewed as insular compared to other developed markets such as Europe or the US, with foreign companies reporting high barriers to entry.
Overall Equipment Effectiveness (OEE)
The primary goal for any manufacturing or process organization is to produce a profit and return on net asset (RONA) to shareholders and other stakeholders. Safety and environmental performance are secondary goals – not secondary in importance, but no manufacturing plant was ever built with the sole and explicit purpose of being safe and environmentally responsible.
Elixir focuses on modern recycling management, expanded product portfolio and service at Prahovo Chemical Park
With 1,650 employees and an annual turnover of EUR 320 million, the Serbian Elixir Group is one of the leading mineral fertilizer and phosphoric acid producers in Eastern Europe.
Proactive Supplier Risk Mitigation for Manufacturing and Testing Organizations
There is a new urgency in the market for manufacturers and testing organizations to be prepared for rapid, unexpected changes in material resource access, exacerbated by turbulent regional and global events. This focus is in addition to reinforcing routine risk mitigation activities around the raw material supply chain, adding to the relevance and impact of the topic.
AI Makes Drug Discovery Faster
Interview with Joachim Haupt and Florian Kaiser, PharmAI
Nanoparticle Engineering
The value in applying AI in Pharma is in making new and better drugs available faster than would be possible otherwise. By augmenting sparse-data AI with expert knowledge and applying it to the latest nanoparticle engineering techniques, opportunities are created to eliminate the risk associated with new techniques and give therapeutics a second chance to reach the patients who need them.
Challenging the Status Quo
Management pays a lot of attention to new ideas and cutting-edge technologies, but most of their resources are consumed by mature legacy technologies that are often not actively and rigorously managed. A visual matrix can help teams understand which technologies offer the greatest long-term potential for businesses.
The Time Has Come
For many years, fine and specialty chemicals markets were on a robust growth path.
An Innovative Wet Sulfuric Acid Process
In many industrial applications the wet sulfuric acid process is the most important technology for recovery of sulfuric acid and energy from sulfur bearing compounds.
Micro- and Millireactors on the Upswing
At an online roundtable event hosted by CHEManager, a group of industry experts discussed the reasons why microreaction technology (MRT) has not achieved the status for instance in fine chemicals and active ingredients production that one might expect as well as various business and production aspects of the technology.
Expanding Into Oligonucleotides
The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment a few years ago and meanwhile has passed certain milestones on its way to become a preferred oligonucleotide manufacturing partner for pharmaceutical companies.
BearingPoint Client Success Story: Boehringer Ingelheim increases Data Accuracy by leveraging Robotic Process Automation
Storage conditions play a vital role in the entire supply chain of pharmaceutical products and must comply with strict regulations. From manufacturers to patients, storage conditions are essential for the quality, safety, and efficacy of medications.
Precision — Passion — Patience
The positive impacts of Predictive Maintenance are broad and should be considered holistically. No one ever said that nurturing a perfect rose garden was simple, but the results can be dramatic.
Enabling the Best Possible Drug
Interview with Oliver Reimann and Andreas Regnery, Belyntic
Making Demanding Applications Bio-Based
Biovox was founded in 2020 to enable more sustainability through renewable bioplastics even in difficult applications such as consumables in healthcare or machine parts.
Easy Access Control
Munio is developing streamlined and efficient learning and access systems that enable business park operators to offer flexibility to their tenants while maintaining control.
Space for Big Ideas
Yncoris has started marketing “The New Knapsite”, one of the largest sites available in Europe for the development of sophisticated process industries and sustainable chemistry of the future. The site offers optimal logistical connections as well as excellent links to the existing Knapsack Chemical Park and the infrastructure it provides.
Multinational Companies in China’s Chemical Industry
Chemical MNCs show strong verbal commitment to China, but the real situation is somewhat underwhelming.
Port of Antwerp Brings Global Chemistry Together
Antwerp is the home port of the largest integrated chemical cluster in Europe. It is the place for entering into partnerships throughout the chain and even across sectors.
